LJM716 ErB2 HER2+ Trastuzumab Novartis TDM, protein-bound paclitaxel, lapatinib ERB2 HER2+ Methodist Hospital System Neratinib ErB2 HER2- Washington University, St. Louis 212Pb-TCMC-Traztu- zumab ErB2 and ER HER2+ Trastuzumab AREVA Med AI, Lapatinib, trastu- zumab ErB2 HER2+_Hormone+ National Cancer Institute Afatinib (BIBW 2992) ErB1/ErB2 HER2+ Vinorelbine Boehringer Ingelheim Afatinib (BIBW 2992) ErB1/ErB2 HER2+ Boehringer Ingelheim Afatinib (BIBW 2992) ErB1/ErB2 HER2+ Alone or with vinorel- bine Boehringer Ingelheim Afatinib (BIBW 2992) ErB1/ErB2 HER2+ Boehringer Ingelheim Neratinib vs. lapatinib ErB1/ErB2 HER2+ Capecitabine Puma Biotechnology Active, not recruiting MM-121 ErB3 Hormone+_HER2- Merrimack Pharmaceuticals IGF Receptors IGF-Methotrexate IGF All University Illinois/IGF Oncology Hormone-mediated Endoxifen Estrogen Re- ceptor Hormone+ National Cancer Institute Z-endoxifen HCl Estrogen Re- ceptor Hormone+ National Cancer Institute Anostrazole + targeted therapies Estrogen Re- ceptor Hormone+ Everolimus, sorafenib, erlotinib, fulvestrant, or bevacizumab MD Anderson Cancer Center ARN-810 Estrogen Re- ceptor Hormone+_HER2- Seragon Pharmaceuticals Enzalutamide Androgen Receptor TripleNegative Medivation/Astellas Pharma Enzalutamide Androgen Receptor Hormone+_HER2- Exemestane Medivation Enzalutamide Androgen receptor All Astellas Pharma Orteronel Androgen receptor Androgen+ Sarah Cannon Research Institute Orteronel CYP17A1/An- drogen Hormone+ University of Wisconsin Cabergoline Prolactin Re- ceptor Prolactin+ Northwestern University Exemestane/cyclophos- phamide Estrogen Rec/ ImmuneCells Hormone+_HER2- New York University Anastrazole vs. fulves- trant Estrogen Re- ceptor Hormone+ Tamoxifen Estrogen Re- ceptor Hormone+ Biomarker analysis CYP2D6 ECOG PTEN Mutation GSK2636771 PTEN Mutation TripleNegative GlaxoSmithKline Other Tetrathiomolybdate Copper All Weill Cornell Medical College MORAb-066 TissueFactor antigen All Morphotek ENMD-2076 Unspecified tyrosine kinase TripleNegative EntreMed Dovitinib FGFR HER2+ Novartis/MD Anderson Cancer Center Active, not recruiting Dovitinib FGFR3 Hormone+_HER2- Aromatase inhibitor Georgetown University Study Drug(s) Target Biomarkers/ Subtype Combination Sponsor